LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 66

Search options

  1. Article ; Online: Landscape and Saturation Analysis of Mutations Associated With Race in Cancer Genomes by Clinical Sequencing.

    Muquith, Maishara / Hsiehchen, David

    The oncologist

    2024  Volume 29, Issue 3, Page(s) 219–226

    Abstract: Differences in cancer genomes between racial groups may impact tumor biology and health disparities. However, the discovery of race-associated mutations is constrained by the limited representation and sample size of different racial groups in prior ... ...

    Abstract Differences in cancer genomes between racial groups may impact tumor biology and health disparities. However, the discovery of race-associated mutations is constrained by the limited representation and sample size of different racial groups in prior genomic studies. We evaluated the influence of race on the frequency of gene mutations using the Genomics, Evidence, Neoplasia, Information, Exchange database, a large genomic dataset aggregated from clinical sequencing. Matched cohort analyses were used to identify histology-specific race-associated mutations including increased TERT promoter mutations in Black and Asian patients with gliomas and bladder cancers, and a decreased frequency of mutations in DNA repair pathway genes and subunits of the SWI/SNF chromatin complex in Asian and Black patients across multiple cancer types. The distribution of actionable mutations in oncogenes was also race-specific, demonstrating how targeted therapies may have a disparate impact on racial groups. Down-sampling analyses indicate that larger sample sizes are likely to discover more race-associated mutations. These results provide a resource to understand differences in cancer genomes between racial groups which may inform the design of clinical studies and patient recruitment strategies in biomarker trials.
    MeSH term(s) Humans ; Mutation ; Racial Groups/genetics ; Urinary Bladder Neoplasms/genetics ; Biomarkers ; Cohort Studies
    Chemical Substances Biomarkers
    Language English
    Publishing date 2024-02-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1093/oncolo/oyad341
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma.

    Whitham, Zachary / Hsiehchen, David

    Surgical oncology clinics of North America

    2023  Volume 33, Issue 1, Page(s) 87–97

    Abstract: Immunotherapy has revolutionized the standard of care in multiple aspects of oncology. Given successes in the setting of unresectable hepatocellular carcinoma (HCC) and the advantages of neoadjuvant therapy, many trials are demonstrating the safety and ... ...

    Abstract Immunotherapy has revolutionized the standard of care in multiple aspects of oncology. Given successes in the setting of unresectable hepatocellular carcinoma (HCC) and the advantages of neoadjuvant therapy, many trials are demonstrating the safety and feasibility of combination of immune checkpoint inhibitors (ICIs)/tyrosine kinases in patients with resectable HCC. Numerous clinical trials are currently investigating the role of different immune modulators either as monotherapy or as combination therapy in the neoadjuvant setting. Key questions that remain to be addressed include efficacy, safety, predictive biomarkers, and length of treatment.
    MeSH term(s) Humans ; Neoadjuvant Therapy ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/surgery ; Liver Neoplasms/drug therapy ; Liver Neoplasms/surgery ; Combined Modality Therapy ; Immunotherapy
    Language English
    Publishing date 2023-08-31
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1196919-2
    ISSN 1558-5042 ; 1055-3207
    ISSN (online) 1558-5042
    ISSN 1055-3207
    DOI 10.1016/j.soc.2023.07.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Lengthy and Variable Delays in Oncology Drug Coverage Determination.

    Haque, Waqas / Rana, Iemaan / Zahid, Sohail / Hsiehchen, David

    JAMA oncology

    2023  Volume 9, Issue 12, Page(s) 1728–1729

    MeSH term(s) Humans ; Insurance Coverage ; Antineoplastic Agents/economics
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2023-10-18
    Publishing country United States
    Document type Journal Article
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2023.4488
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.

    Lim, Mir / Lynch, Patrick T / Bai, Xiaochen / Hsiehchen, David

    JCO precision oncology

    2023  Volume 7, Page(s) e2200340

    MeSH term(s) Humans ; Ligands ; Cholangiocarcinoma/drug therapy ; Cholangiocarcinoma/genetics ; Bile Ducts, Intrahepatic/pathology ; Bile Duct Neoplasms/drug therapy ; Bile Duct Neoplasms/genetics ; Bile Duct Neoplasms/pathology ; Receptor, Fibroblast Growth Factor, Type 2/genetics
    Chemical Substances pemigatinib (Y6BX7BL23K) ; Ligands ; FGFR2 protein, human (EC 2.7.10.1) ; Receptor, Fibroblast Growth Factor, Type 2 (EC 2.7.10.1)
    Language English
    Publishing date 2023-01-09
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.22.00340
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Reversal of Hepatic Dysfunction After Exceptional Responses to Lenvatinib.

    Muquith, Maishara / Espinoza, Magdalena / Hsiehchen, David

    Journal of gastrointestinal cancer

    2022  Volume 54, Issue 3, Page(s) 982–985

    MeSH term(s) Humans ; Liver Neoplasms/drug therapy ; Phenylurea Compounds/adverse effects ; Quinolines/adverse effects ; Carcinoma, Hepatocellular/drug therapy
    Chemical Substances lenvatinib (EE083865G2) ; Phenylurea Compounds ; Quinolines
    Language English
    Publishing date 2022-08-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2452514-5
    ISSN 1941-6636 ; 1559-0739 ; 1941-6628 ; 1537-3649
    ISSN (online) 1941-6636 ; 1559-0739
    ISSN 1941-6628 ; 1537-3649
    DOI 10.1007/s12029-022-00852-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Representation of Investigators by Gender Among Authors of Phase 3 Oncology Trials Worldwide.

    Muquith, Maishara / Pham, Tri / Espinoza, Magdalena / Hsiehchen, David

    JAMA network open

    2022  Volume 5, Issue 2, Page(s) e220031

    MeSH term(s) Clinical Trials, Phase III as Topic/statistics & numerical data ; Female ; Humans ; Male ; Neoplasms/drug therapy ; Oncologists/statistics & numerical data ; Research Personnel/statistics & numerical data ; Sex Distribution
    Language English
    Publishing date 2022-02-01
    Publishing country United States
    Document type Journal Article
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2022.0031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma.

    Lim, Mir / Muquith, Maishara / Miramontes, Bernadette / Espinoza, Magdalena / Hsiehchen, David

    Cancer research communications

    2023  Volume 3, Issue 9, Page(s) 1912–1916

    Abstract: Immune checkpoint inhibitors (ICI) can induce atypical tumor responses including pseudoprogression in a subset of patients who may benefit from treatment beyond progression. While ICIs have emerged as frontline treatments for hepatocellular carcinoma ( ... ...

    Abstract Immune checkpoint inhibitors (ICI) can induce atypical tumor responses including pseudoprogression in a subset of patients who may benefit from treatment beyond progression. While ICIs have emerged as frontline treatments for hepatocellular carcinoma (HCC) and are associated with clinical benefit in a minority of patients, it is unclear whether treatment beyond progression has utility in this disease type. In a multicenter cohort analysis, treatment beyond progression was associated with no new safety signals, objective responses in 5.8% of patients, and disease control in 44% of patients. Progression-free survival and overall survival were comparable between patients treated beyond progression and patients treated with subsequent therapies, demonstrating that treatment beyond progression was not detrimental to survival outcomes. Rather, treatment beyond progression may benefit select patients with HCC and could represent a viable strategy for maximizing treatment benefit in these patients.
    Significance: Treatment beyond progression with ICIs in patients with HCC is safe and may benefit a subset of patients due to later-onset tumor responses or disease stability. These findings may guide the design of trials testing ICIs in HCC and the use of treatment beyond progression in routine practice.
    MeSH term(s) Humans ; Carcinoma, Hepatocellular/drug therapy ; Liver Neoplasms/drug therapy
    Language English
    Publishing date 2023-09-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2767-9764
    ISSN (online) 2767-9764
    DOI 10.1158/2767-9764.CRC-23-0025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit.

    Dong, Sharlene / Zakaria, Heba / Hsiehchen, David

    The oncologist

    2022  Volume 27, Issue 3, Page(s) 159–162

    Abstract: Inactivating mutations in the exonuclease domain of POLE induce somatic hypermutation resulting in a high tumor mutation burden (TMB) and are associated with immune checkpoint inhibitor (ICI) benefit. POLE mutations outside the exonuclease domain ... ...

    Abstract Inactivating mutations in the exonuclease domain of POLE induce somatic hypermutation resulting in a high tumor mutation burden (TMB) and are associated with immune checkpoint inhibitor (ICI) benefit. POLE mutations outside the exonuclease domain predicted to be deleterious are also observed in cancers, but it is unknown whether they are similarly associated with response to ICIs. We present a patient with hepatocellular carcinoma with a rare POLE mutation (V1368M) outside the exonuclease-domain predicted to be deleterious, a low TMB (1 mut/Mb), and microsatellite stability, who demonstrated an exceptional response to pembrolizumab. To support the generalizability of this finding, an analysis of 1278 patients with advanced cancers harboring low or intermediate TMB treated with ICIs showed that missense non-exonuclease domain POLE mutations were associated with greater overall survival. In contrast, among patients with advanced cancers without ICI exposure, POLE mutations were not associated with overall survival. These results demonstrate that a subset of missense POLE mutations may represent predictive biomarkers independent of TMB. Pathogenic POLE mutations outside the exonuclease domain may result in altered functions beyond DNA replication and proofreading which render cancers sensitive to ICIs.
    MeSH term(s) Biomarkers, Tumor/genetics ; Exonucleases/genetics ; Humans ; Immunotherapy ; Mutation ; Neoplasms/drug therapy ; Neoplasms/genetics
    Chemical Substances Biomarkers, Tumor ; Exonucleases (EC 3.1.-)
    Language English
    Publishing date 2022-03-11
    Publishing country England
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1093/oncolo/oyac017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Characteristics of Faculty Accused of Academic Sexual Misconduct in the Biomedical and Health Sciences.

    Espinoza, Magdalena / Hsiehchen, David

    JAMA

    2020  Volume 323, Issue 15, Page(s) 1503–1505

    MeSH term(s) Biomedical Research ; Faculty/statistics & numerical data ; Female ; Humans ; Male ; Rape/statistics & numerical data ; Schools, Health Occupations/organization & administration ; Sexism/statistics & numerical data ; Sexual Harassment/statistics & numerical data ; Universities/organization & administration
    Language English
    Publishing date 2020-04-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2020.1810
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150.

    Espinoza, Magdalena / Muquith, Maishara / Lim, Mir / Zhu, Hao / Singal, Amit G / Hsiehchen, David

    Gastroenterology

    2023  Volume 165, Issue 1, Page(s) 286–288.e4

    MeSH term(s) Humans ; Carcinoma, Hepatocellular/drug therapy ; Bevacizumab/adverse effects ; Liver Neoplasms/drug therapy ; Causality
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; atezolizumab (52CMI0WC3Y)
    Language English
    Publishing date 2023-03-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2023.02.042
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top